Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia.

ABSTRACT: Diagnosing ventilator-associated pneumonia (VAP) remains challenging. Soluble urokinase plasminogen activator receptor (suPAR) has prognostic value in critically ill patients with systemic infection. We hypothesised that plasma suPAR levels accurately predict development of VAP. This observational, multicentre, prospective cohort study compared patients at risk for VAP with a control group. Plasma and tracheal aspirate samples were collected. Plasma suPAR levels were measured on the day of diagnosis and 3 days before diagnosis. The study included 24 VAP patients and 19 control patients. The suPAR concentration measured 3 days before diagnosis was significantly increased in VAP patients versus matched samples of control patients (area under the receiver operating characteristic curve (AUC)

SUBMITTER: van Oort PM 

PROVIDER: S-EPMC6431752 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature